- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Tony Coles, the former CEO of Onyx sold to Amgen for $10 billion in late 2013, is launching Yumanity Therapeutics focused on developing drugs for neuro-degenerative diseases.
The CEOs of Exact Sciences, Idenix Pharma, Prosensa, Agios, Bluebird Bio and InterMune vie for the coveted title of Best Biotech CEO
Five of 27 patients with an aggressive and hard-to-treat form of breast cancer responded to treatment with Merck's checkpoint inhibitor Keytruda.
Beta-thalassemia patients no longer require blood transfusions following a single treatment with Bluebird's LentiGlobin gene therapy.
Here's what I learned about biotech and drug stocks after covering the American Society of Hematology annual meeting.
Sunesis' experimental leukemia drug vosaroxin underwent a miraculous transformation during a Sunday morning press briefing at the American Society of Hematology.
Celgene has worldwide clinical development and marketing rights to the two Acceleron drugs, known as luspatercept and sotatercept.
Agios and Celgene are accelerating development of AG-221 based on updated results from an early study showing strong and durable activity.
A new form of cancer immunotherapy known as CAR-T promises to radically change the way certain blood cancers are treated.
Checkpoint inhibitors can prime a patient's own immune system to kill certain types of blood cancer cells just like they do with solid tumors such as melanoma and lung cancer.